Seminars in Nuclear Medicine
Volume 34, Issue 1, Supplement , Pages 10-13 , January 2004

Imaging and dosing in radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin)

  • Stewart M. Spies

      Affiliations

    • Department of Nuclear Medicine, Northwestern Memorial Hospital, Chicago, IL, USA
    • *Address reprint requests to Stewart M. Spies, MD, Director, Nuclear Medicine, Northwestern Memorial Hospital, 201 E. Huron, Galter 8-104, Chicago, IL 60611, USA
    • 1Dr Spies has received honoraria from Biogen Idec Inc.

References 

  1. Potamianos S, Varvarigou AD, Archimandritis SC. Radioimmunoscintigraphy and radioimmunotherapy in cancer: Principles and application. Anticancer Res. 2000;20:925–948
  2. Wiseman GA, White CA, Sparks RB, et al.  Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Crit Rev Oncol Hematol. 2001;39:181–194
  3. Lamb HM, Faulds D. Capromab pendetide. A review of its use as an imaging agent in prostate cancer. Drugs Aging. 1998;12:293–304
  4. Pinkas L, Robins PD, Forstrom LA, et al.  Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature. Nucl Med Commun. 1999;20:689–696
  5. Leitha T, Walter R, Schlick W, et al.  99mTc-anti-CEA radioimmunoscintigraphy of lung adenocarcinoma. Chest. 1991;99:14–19
  6. Illidge TM, Johnson PW. The emerging role of radioimmunotherapy in haematological malignancies. Br J Haematol. 2000;108:679–688
  7. Anderson KC, Bates MP, Slaughenhoupt BL, et al.  Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984;63:1424–1433
  8. Zelenetz AD. Radioimmunotherapy for lymphoma. Curr Opin Oncol. 1999;11:375–380
  9. Wiseman GA, White CA, Witzig TE, et al.  Radioimmunotherapy of relapsed non-Hodgkin’s lymphoma with Zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res. 1999;5:3281s–3286s
  10. Colcher D. Centralized radiolabeling of antibodies for radioimmunotherapy. J Nucl Med. 1998;39:11S–13S
  11. Wiseman GA, Leigh B, Erwin WD, et al.  Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer. 2002;94:1349–1357
  12. Knox SJ, Goris ML, Trisler K, et al.  Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457–470
  13. Zevalin (ibritumomab tiuxetan) prescribing information. Cambridge, MA: Biogen Idec Inc,; 2002;
  14. Biogen Idec imaging atlas. Cambridge, MA: Biogen Idec Inc,; 2002;
  15. Wiseman GA, White CA, Stabin M, et al.  Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma. Eur J Nucl Med. 2000;27:766–777

PII: S0001-2998(03)00081-3

doi: 10.1053/j.semnuclmed.2003.11.004

Seminars in Nuclear Medicine
Volume 34, Issue 1, Supplement , Pages 10-13 , January 2004

Article Tools

* Image Usage & Resolution